Keap1 inhibition attenuates glomerulosclerosis

Nephrology Dialysis Transplantation

Volumn 29, Issue 4, 2014, Pages 783-791

  Miyazaki, Yoichi ^a   Shimizu, Akihiro ^a,b   Pastan, Ira ^c   Taguchi, Keiko ^d   Naganuma, Eriko ^d   Suzuki, Takafumi ^d   Hosoya, Tatsuo ^a   Yokoo, Takashi ^a   Saito, Akihiko ^e   Miyata, Toshio ^d   Yamamoto, Masayuki ^d   Matsusaka, Taiji ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

antioxidant genes; glomerulosclerosis; hypomorphic allele; oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; CREATININE; DESMIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MEGALIN; MESSENGER RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NRF2;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COL1A2 GENE; COL4A4 GENE; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE COURSE; ENZYME PHOSPHORYLATION; FEMALE; FN1 GENE; GCLC GENE; GCLM GENE; GENE; GENE EXPRESSION; GLOMERULOSCLEROSIS; GSTP1 GENE; GSTP2 GENE; KEAP1 GENE; MALE; MOUSE; NONHUMAN; NQO1 GENE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; REAL TIME POLYMERASE CHAIN REACTION; TGFB1 GENE; TRANSCRIPTION INITIATION; UPREGULATION;

ANTIOXIDANT GENES; GLOMERULOSCLEROSIS; HYPOMORPHIC ALLELE; OXIDATIVE STRESS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ALLELES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIOXIDANTS; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; DNA; EXOTOXINS; FEMALE; GENE EXPRESSION REGULATION; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; IMMUNOTOXINS; KIDNEY GLOMERULUS; MALE; MICE; MICE, MUTANT STRAINS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PODOCYTES; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84897468255     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu002     Document Type: Article

References (58)

1. Kwoh C, Shannon MB, Miner JH et al. Pathogenesis of nonimmune glomerulopathies. Annu Rev Pathol 2006; 1: 349-374
2. LeHir M, Kriz W. New insights into structural patterns encountered in glomerulosclerosis. Curr Opin Nephrol Hypertens 2007; 16: 184-191
3. Pollak MR. Focal segmental glomerulosclerosis: Recent advances. Curr Opin Nephrol Hypertens 2008; 17: 138-142
4. Machuca E, Benoit G, Antignac C. Genetics of nephrotic syndrome: Connecting molecular genetics to podocyte physiology. Hum Mol Genet 2009; 18: R185-R194
5. Patrakka J, Tryggvason K. New insights into the role of podocytes in proteinuria. Nat Rev Nephrol 2009; 5: 463-468
6. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 2006; 354: 1387-1401
7. Zenker M, Machuca E, Antignac C. Genetics of nephrotic syndrome: New insights into molecules acting at the glomerular filtration barrier. J Mol Med 2009; 87: 849-857
8. Shah SN, He CJ, Klotman P. Update on HIV-Associated nephropathy. Curr Opin Nephrol Hypertens 2006; 15: 450-455
9. Stitt-Cavanagh E, MacLeod L, Kennedy C. The podocyte in diabetic kidney disease. SciWorld J 2009; 9: 1127-1139
10. Binder CJ, Weiher H, Exner M et al. Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy. Am J Pathol 1999; 154: 1067-1075
11. Greiber S, Munzel T, Kastner S et al. NAD(P)H oxidase activity in cultured human podocytes: Effects of adenosine triphosphate. Kidney Int 1998; 53: 654-663
12. Itoh K, Wakabayashi N, Katoh Y et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-Terminal Neh2 domain. Genes Dev 1999; 13: 76-86
13. Kobayashi A, Kang MI, Okawa H et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004; 24: 7130-7139
14. Itoh K, Chiba T, Takahashi S et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236: 313-322
15. Wakabayashi N, Itoh K, Wakabayashi J et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 2003; 35: 238-245
16. Kensler TW, Wakabayashi N. Nrf2: Friend or foe for chemoprevention? Carcinogenesis 2010; 31: 90-99
17. Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 2004; 10: 549-557
18. Sykiotis GP, Bohmann D. Stress-Activated cap'n'collar transcription factors in aging and human disease. Sci Signal 2010; 3: Re3
19. Thimmulappa RK, Lee H, Rangasamy T et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 2006; 116: 984-995
20. Thimmulappa RK, Scollick C, Traore K et al. Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. Biochem Biophys Res Commun 2006; 351: 883-889
21. Cho HY, Jedlicka AE, Reddy SP et al. Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 2002; 26: 175-182
22. Cho HY, Reddy SP, Debiase A et al. Gene expression profiling of NRF2 mediated protection against oxidative injury. Free Radic Biol Med 2005; 38: 325-343
23. Cho HY, Reddy SP, Yamamoto M et al. The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J 2004; 18: 1258-1260
24. Rangasamy T, Guo J, Mitzner WA et al. Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med 2005; 202: 47-59
25. Rangasamy T, Cho CY, Thimmulappa RK et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 2004; 114: 1248-1259
26. Shih AY, Li P, Murphy TH. A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J Neurosci 2005; 25: 10321-10335
27. Zhao J, Kobori N, Aronowski J et al. Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neurosci Lett 2006; 393: 108-112
28. Taguchi K, Maher JM, Suzuki T et al. Genetic analysis of cytoprotective functions supported by graded expression of Keap1. Mol Cell Biol 2010; 30: 3016-3026
29. Jiang T, Huang Z, Lin Y et al. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 2010; 59: 850-860
30. Zheng H, Whitman SA, WuWet al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 2011; 60: 3055-3066
31. Liu M, Grigoryev1 DN, Crow MT et al. Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int 2009; 76: 277-285
32. Tsai P-Y, Ka S-M, Chao T-K et al. Antroquinonol reduces oxidative stress by enhancing the Nrf2 signaling pathway and inhibits inflammation and sclerosis in focal segmental glomerulosclerosis mice. Free Radic Biol Med 2011; 50: 1503-1516
33. Matsusaka T, Xin J, Niwa S et al. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol 2005; 16: 1013-1023
34. Matsusaka T, Asano T, Niimura F et al. Angiotensin receptor blocker protection against podocyte-induced sclerosis is podocyte angiotensin II type 1 receptor-independent. Hypertension 2010; 55: 967-973
35. Okawa H, Motohashi H, Kobayashi A et al. Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem Biophys Res Commun 2006; 339: 79-88
36. Kanehira T, Takekoshi S, Nagata H et al. A novel and potent biological antioxidant, Kinobeon A, from cell culture of safflower. Life Sci 2003; 74: 87-97
37. Onouchi H, Ishii T, Miyazawa M et al. Mitochondrial superoxide anion overproduction in Tet-mev-1 transgenic mice accelerates age-dependent corneal cell dysfunctions. Invest Ophthalmol Vis Sci 2012; 53: 5780-5787
38. Reisman SA, Chertow GM, Hebbar S et al. Bardoxolone methyl decreases megalin and activates Nrf2 in the kidney. J Am Soc Nephrol 2012; 23: 1663-1673
39. Motoyoshi Y, Matsusaka T, Saito A et al. Megalin contributes to the early injury of proximal tubule cells during nonselective proteinuria. Kidney Int 2008; 74: 1262-1269
40. Matsusaka T, Sandgren E, Shintani A et al. Podocyte injury damages other podocytes. J Am Soc Nephrol 2011; 22: 1275-1285
41. Diamond JR, Bonventre JV, Karnovsky MJ. A role for oxygen free radicals in aminonucleoside nephrosis. Kidney Int 1986; 29: 478-483
42. Thakur V, Walker PD, Shah SV. Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria. Kidney Int 1988; 34: 494-499
43. GwinnerW, Landmesser U, Brandes RP et al. Reactive oxygen species and antioxidant defense in puromycin aminonucleoside glomerulopathy. J Am Soc Nephrol 1997; 8: 1722-1731
44. Marshall CB, Pippin JW, Krofft RD et al. Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo. Kidney Int 2006; 70: 1962-1973
45. Kinugasa S, Tojo A, Sakai T et al. Selective albuminuria via podocyte albumin transport in puromycin nephrotic rats is attenuated by an inhibitor of NADPH oxidase. Kidney Int 2011; 80: 1328-1338
46. Hayden MR, Whaley-Connell A, Sowers Jr. Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: Paying homage to the podocyte. Am J Nephrol 2005; 25: 553-569
47. Piwkowska A, Rogacka D, Audzeyenka I et al. High glucose concentration affects the oxidant-Antioxidant balance in cultured mouse podocytes. J Cell Biochem 2011; 112: 1661-1672
48. Zheng S, Carlson EC, Yang L et al. Podocyte-specific overexpression of the antioxidant metallothionein reduces diabetic nephropathy. J Am Soc Nephrol 2008; 19: 2077-2085
49. Susztak K, Raff AC, Schiffer M et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 225-233
50. Dinkova-Kostova AT, Liby KT, Stephenson KK et al. Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 2005; 102: 4584-4589
51. Yates MS, Tauchi M, Katsuoka F et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 2007; 6: 154-162
52. Sporn MB, Liby KT, Yore MM et al. New synthetic triterpenoids: Potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod 2011; 74: 537-545
53. Pergola PE, Raskin P, Toto RD et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365: 327-336
54. Ruiz S, Pergola PE, Zager RA et al. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int 2013; 83: 1029-1041
55. Zoja C, Benigni A, Remuzzi G. The Nrf2 pathway in the progression of renal disease. Nephrol Dial Transplant 2014; 29(Suppl 1):i19-i24
56. Hagemann JH, Thomasova D, Mulay SR et al. Nrf2 signalling promotes ex vivo tubular epithelial cell survival and regeneration via murine double minute (MDM)-2. Nephrol Dial Transplant 2013; 28: 2028-2037
57. Yoh K, Hirayama A, Ishizaki K et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells 2008; 13: 1159-1170
58. Yu D, Petermann A, Kunter U et al. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 2005; 16: 1733-1741